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Effect of Montelukast Treatment on Serum
Paraoxonase Activity in Asthmatic Children
Abstract: Montelukast, widely used in the treatment of asthma, is a selective and potent oral cysteinyl
leukotriene-1 receptor antagonist. In this study, we investigated the effects of montelukast on oxidative stress
and antioxidant defense in childhood asthma by measuring malondialdehyde and the paraoxonase activity.
Twenty-five children with mild to moderate atopic asthma and 25 nonatopic children as controls were enrolled
in the study. Asthmatic children were treated with montelukast, 5 mg tablets, for one month. Serum
paraoxonase, malondialdehyde and high-density lipoprotein (HDL) cholesterol levels were measured before and
after treatment. Serum paraoxonase and paraoxonase/HDL ratios were significantly increased after
montelukast treatment. These parameters were significantly higher when compared with the normal subjects.
Although montelukast treatment caused an enhancement in serum malondialdehyde, this increase did not reach
statistical significance between the groups. The present study clearly demonstrates that montelukast increases
paraoxonase activity in children with bronchial asthma. However, for better understanding of this
enhancement, additional in vivo and in vitro studies are required.
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Ast›ml› Çocuklarda Montelukast Tedavisinin Serum
Paraoksonaz Aktivitesi Üzerine Etkisi
Amaç: Montelukast, ast›m tedavisinde yayg›n olarak kullan›lan selektif ve etkili oral sistein lökotrien 1 reseptör
antagonistidir. Bu çal›ﬂmam›zda, malondialdehit düzeylerini ve paraoksonaz aktivitesini ölçerek, çocukluk ça¤›
ast›m hastalar›nda oksidatif hasar ve antioksidan defans üzerine montelukast’›n etkilerini araﬂt›rd›k. Hafif ve
orta derecede atopik ast›ml› 25 çocuk hasta grubu olarak ve 25 non-atopik sa¤l›kl› çocuk kontrol grubu olarak
çal›ﬂmaya dahil edildi. Ast›ml› çocuklar bir ay boyunca 5 mg montelukast ile tedavi edildi. Serum paraoksonaz,
malondialdehit ve HDL kolesterol seviyeleri tedavi öncesi ve sonras› ölçüldü. Montelukast tedavisi sonras› serum
paraoksonaz ve paraoksonaz/HDL oran› anlaml› bir art›ﬂ gösterdi. Kontrol grubu ile k›yasland›¤›nda bu
parametreler belirgin olarak yüksek bulundu. Montelukast tedavisi serum malondialdehit düzeylerinde bir
art›ﬂa neden olmakla beraber, bu de¤iﬂim istatistiksel olarak anlaml› de¤ildi. Bu çal›ﬂmada montelukast’›n
bronﬂial ast›ml› çocuklarda serum paraoksonaz aktivitesini etkin biçimde artt›rd›¤› görüldü. Bu konuda
yap›lacak in vivo ve in vitro çal›ﬂmalar›n bu mekanizmay› ayd›nlatma konusunda faydal› olabilece¤ini
düﬂünüyoruz.
Anahtar Sözcükler: Montelukast, ast›m, paraoksonaz
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Asthma is a chronic airway disease. Although the exact mechanism of the
pathogenesis of asthma is unknown, it is characterized with chronic inflammation by an
activation of inflammatory cells, generation of inflammatory mediators, and epithelial
cell shedding (1).
The inflammatory cells infiltrating the airways, such as macrophages, neutrophils,
and eosinophils, release increased amounts of reactive oxygen species (ROS) in asthmatic
patients (2). Increased production of ROS leading to an imbalance between the oxidative
stress and antioxidant defense systems causes an oxidative injury in asthma (3). ROS can
produce many of the pathological properties of asthma, including increased airway
reactivity and secretions, production of chemoattractant molecules, and increased
vascular permeability (4-6). These oxygen intermediates also affect lipid and lipoproteins
and result in their oxidation yielding oxidation products. Paraoxonase, a constituent of
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high-density lipoprotein (HDL) recognized as an
antioxidant enzyme, metabolizes and detoxifies
biologically active lipid peroxides.
Montelukast is a potent, selective reversible oral
cysteinyl leukotriene-1 (CysLT1) receptor antagonist and
is widely used in the treatment of asthma (7). Many
studies have established the determinants of oxidative
stress and antioxidant defense in children with asthma.
However, to our knowledge, this is the first study to
compare antioxidant effects of montelukast through the
paraoxonase activity.
Based on these findings, we investigated the effects of
montelukast on oxidative stress and antioxidant defense
in childhood asthma by measuring malondialdehyde and
the paraoxonase activity.

Materials and Methods
Twenty-five children with mild to moderate atopic
asthma and 25 nonatopic children as controls were
enrolled in the study. The diagnosis was established on
the basis of medical history, physical examination and
atopy according to the Third International Pediatric
Consensus (8); bronchial provocation test was not
performed. Atopic status of all patients was defined by
positive skin prick tests for at least one positive response
to an allergen (a mean weal diameter > 3 mm was
defined as positive control and diluent was considered as
negative control). Asthma symptoms were evaluated by a
single observer before any laboratory measurements
were made.
Asthma symptoms were evaluated with a screening
questionnaire based on the Pediatric Asthma Quality of
Life Questionnaire and both daytime and nocturnal
asthma symptom diary scales (9,10). Patients were
scored by a single observer before any laboratory
measurements were made. For each of the day and night
observations, a score of 1–4 was assigned (0: No
symptoms day/night; 1: One or two symptoms day/night;
2: More than two symptoms day/night; 3: Symptoms that
affect one or two daily activities/disturb sleep most of the
night; and 4: Symptoms that affect more than two daily
activities/disturb sleep all night), resulting in a possible
minimum score of 0 and a maximum score of 4.
The patients were classified into mild to moderate
asthma according to the symptoms. In the month prior to
374
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the study, none of the patients was treated with inhaled
corticosteroids, leukotriene antagonist or long-acting β
agonist. No evidence of pulmonary infection was detected
and no patients required antibiotics. The Ethical Review
Committee and Institutional Review Boards approved the
study and all of the subjects gave written informed
consent from their parents.
This trial investigated the effects of montelukast
sodium (Singulair, MSD, NJ, USA) 5 mg tablets in
children. There were three study visits. At the first visit,
we enrolled 25 patients and gave them β2-agonist
(Ventolin, Glaxo Wellcome, London, UK) 100 µg four
times daily for one month. They were informed of the
purpose of the study and were told how to score asthma
symptoms and use the inhaler. At the second visit,
subjects were treated with montelukast. The third visit
was after one month of the treatment. Blood collection
and lung function test were performed on the same day
of the second and third visits.
Serum samples were collected into Becton Dickinson
serum separator tubes, containing no anticoagulant. After
clot formation was completed, samples were centrifuged
at 3500 rpm for five minutes and frozen at –80°C.
Frozen samples were mixed thoroughly after thawing and
recentrifuged before analysis. Repeat freeze-thaw cycles
were avoided.
Malondialdehyde measurement was assayed on UV1601 Shimadzu spectrophotometer by Hunter’s method
with standard 1,1,3,3 tetra-etoxypropane and results are
expressed as nmol/ml (11). Paraoxonase activities were
measured according to Gan et al. (12), using paraoxon as
substrate, in the presence of 1 mM Ca+2 in 100 mM TrisHCl buffer (pH 8.0) and results were expressed as U/L.
Serum HDL-cholesterol levels were measured by
enzymatic colorimetric methods with commercially
available kits on Roche Integra 800.
The study group comparisons were assessed by
Wilcoxon matched pairs signed rank test to evaluate two
related samples before and after treatment. The
comparisons between asthma patients and normal
subjects were done by Mann-Whitney U rank sum test.

Results
The demographic characteristics of the subjects are
outlined in Table 1 and there was no significant difference
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between groups. After the treatment period, all patients
experienced significant improvements in symptom scores
and forced expiratory volume in 1 second (FEV1) levels
(Table 2).
Serum paraoxonase and paraoxonase/HDL ratios were
significantly increased after montelukast treatment.
These parameters were significantly higher when
compared with the normal subjects. Although
montelukast treatment caused an enhancement in serum
malondialdehyde, this increase did not reach statistical
significance between the groups (Table 3).

Discussion
Montelukast is regarded as an effective and reliable
drug of choice in the treatment of bronchial asthma (13).
It has been demonstrated that montelukast reduced the
number of eosinophils in bronchoalveolar lavage fluid in
experimental allergic asthma and in peripheral blood,
bronchial mucosa, and sputum of asthmatic subjects
(14,15). Treatment period with montelukast did not
significantly affect neutrophil chemotaxis or phagocytosis
nor the elevated superoxide production (16). Gurer et al.
(17) found that montelukast treatment increased the
phagocytic and intracellular killing activity of
polymorphonuclear leukocytes in patients with bronchial
asthma.

Table 1. Demographic characteristics of the subjects.

Male/Female
Age (years)
Weight (kg)
Disease duration (years)

Patients
(n=25)

Controls
(n=25)

11/14
9.4±0.4
31.2±.4
5.7±0.2

14/11
10.3±0.4
32.5±2.2
-
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Malondialdehyde level is an indicator of lipid
peroxidation of the membranes that results from
oxidative damage. In our study, malondialdehyde
concentrations were higher after montelukast treatment
and these levels were found to be higher than those of
the control group, but this increase did not reach
statistical significance between the groups. This
observation suggests that elevated lipid peroxidation may
partly be due to the free radicals generated by leukocytes
or neutrophils and that montelukast is enough to prevent
further increases in lipid peroxidation.
In a recent study, Ekmekci et al. (18) studied the role
of paraoxonase in adult asthmatic patients and no
significant difference was found between the control and
patient groups. Similarly, an insignificant decrease was
detected in children during bronchial asthma exacerbation
(19). In accordance with these findings, in the present
study, there was no difference in the plasma levels of
paraoxonase before montelukast treatment compared
with those of the control group. Collectively, these
observations suggest that bronchial asthma causes no
significant change in serum paraoxonase levels.
Paraoxonase is predominantly produced in the liver
(20). Feingold et al. (21) showed that tumor necrosis
factor (TNF)-α administration decreased both
paraoxonase activity and mRNA levels in the hamster
liver. As reported by Kumon (22), paraoxonase was
Table 2. Clinical and functional measurements.

FEV1 (%)
Symptom scores (day)
Symptom scores (night)

Before Montelukast
(n=25)

After Montelukast
(n=25)

85.9±3.6*
2.9±0.8*
1.4±0.5*

98.9±2.6
0.7±0.4
0.3±0.3

* P<0.05, compared to Montelukast-treated group.

Table 3. Comparison of parameters before and after treatment and in control subjects.

Paraoxonase (U/L)
HDL-cholesterol (mg/L)
Paraoxonase/HDL (U/mg)
Malondialdehyde (nmol/ml)

Before Montelukast
(n=25)

After Montelukast
(n=25)

Control
(n=25)

211.0±123.2*
486±116
4.7±3.4*
4.2±0.2

323.2±189.7**
496±128
6.9±4.2**
4.7±0.6

230.5±108.7
503±108
4.9±2.8
4.6±0.4

* P<0.05, compared to Montelukast-treated group.
** P<0.05, compared to Control group.
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downregulated by TNF-α, and this was concordant with
the result of paraoxonase mRNA expression by HepG2
cells in response to the cytokines. The findings of our
previous trial in asthmatic children revealed that
montelukast significantly reduced the serum
concentration of TNF-α (23). In this study, after one
month of treatment with montelukast, we observed a
significant increase in paraoxonase activity. These findings
and the results of the present study suggest that the
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increase in serum paraoxonase activity may be due to a
reduction in TNF-α synthesis or secretion which directly
causes liver cells to increase paraoxonase mRNA.
In conclusion, the present study clearly demonstrates
that montelukast, a CysLT1 receptor antagonist,
increases paraoxonase activity in children with bronchial
asthma. However, for better understanding of this
enhancement, additional in vivo and in vitro studies are
required.
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